Capital International Investors Sells 2,552,261 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Capital International Investors trimmed its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 64.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,418,602 shares of the biopharmaceutical company's stock after selling 2,552,261 shares during the period. Capital International Investors owned approximately 1.10% of Alnylam Pharmaceuticals worth $333,833,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Allworth Financial LP grew its stake in shares of Alnylam Pharmaceuticals by 6.8% during the 4th quarter. Allworth Financial LP now owns 597 shares of the biopharmaceutical company's stock worth $140,000 after acquiring an additional 38 shares in the last quarter. Nixon Peabody Trust Co. grew its position in Alnylam Pharmaceuticals by 1.9% in the fourth quarter. Nixon Peabody Trust Co. now owns 2,293 shares of the biopharmaceutical company's stock valued at $540,000 after purchasing an additional 43 shares in the last quarter. IFP Advisors Inc increased its stake in Alnylam Pharmaceuticals by 24.2% in the 4th quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company's stock valued at $57,000 after buying an additional 47 shares during the last quarter. Nwam LLC lifted its position in Alnylam Pharmaceuticals by 5.8% during the 4th quarter. Nwam LLC now owns 906 shares of the biopharmaceutical company's stock worth $213,000 after buying an additional 50 shares in the last quarter. Finally, National Bank of Canada FI boosted its stake in shares of Alnylam Pharmaceuticals by 9.0% during the 4th quarter. National Bank of Canada FI now owns 668 shares of the biopharmaceutical company's stock worth $157,000 after buying an additional 55 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company's stock.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock traded down $1.47 during trading hours on Thursday, reaching $240.50. 222,847 shares of the stock were exchanged, compared to its average volume of 872,598. The stock has a 50 day moving average of $247.62 and a two-hundred day moving average of $256.40. The company has a market cap of $31.29 billion, a P/E ratio of -110.94 and a beta of 0.30. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. Alnylam Pharmaceuticals, Inc. has a twelve month low of $141.98 and a twelve month high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.03). Equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the company's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $251.56, for a total value of $362,246.40. Following the sale, the executive vice president now owns 12,881 shares in the company, valued at approximately $3,240,344.36. The trade was a 10.06 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CMO Pushkal Garg sold 52,592 shares of the stock in a transaction that occurred on Monday, January 27th. The shares were sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the sale, the chief marketing officer now directly owns 11,989 shares of the company's stock, valued at $3,416,865. This represents a 81.44 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 59,984 shares of company stock worth $16,864,347 over the last 90 days. Insiders own 1.20% of the company's stock.

Analysts Set New Price Targets

Several research analysts recently commented on ALNY shares. Scotiabank increased their price target on Alnylam Pharmaceuticals from $338.00 to $342.00 and gave the company a "sector outperform" rating in a research report on Monday, March 31st. Sanford C. Bernstein decreased their target price on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an "outperform" rating for the company in a research note on Tuesday, January 7th. JPMorgan Chase & Co. raised shares of Alnylam Pharmaceuticals from a "neutral" rating to an "overweight" rating and upped their price target for the stock from $280.00 to $328.00 in a research report on Monday, March 24th. Redburn Atlantic initiated coverage on shares of Alnylam Pharmaceuticals in a research report on Monday, March 31st. They issued a "buy" rating and a $353.00 price objective for the company. Finally, Royal Bank of Canada upped their target price on shares of Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the company an "outperform" rating in a report on Friday, March 21st. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and twenty-two have given a buy rating to the company. Based on data from MarketBeat.com, Alnylam Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus price target of $315.58.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.